Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

H. Ludwig(Universitätsmedizin Göttingen), N. Zojer(Charles University), Ingrid Kühn, Heinz Gisslinger(Medical University of Vienna), Zdeněk Adam, Axel Hinke, Roman Hájek(University Hospital Ostrava), Johannes Drach(Vienna General Hospital), E Tóthová, Boris Labar(University Hospital Centre Zagreb), Miklós Egyed(Somogy Megyei Kaposi Mór Oktató Kórház)

Haematologica

April 23, 2010

10.3324/haematol.2009.020586

Cited by 70

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

|Leukemia|2009|877

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

|Leukemia|2008|808

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

|European Journal of Cancer|2011|615

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

|Blood|2012|596